FindTrial
Sign In

AZD3759

DRUG4 trials

Sponsors

AstraZeneca, LYZZ Alpha Holding Ltd, Guangdong Association of Clinical Trials, Alpha Biopharma (Jiangsu) Co., Ltd.

Conditions

Brain MetastasesCarcinoma, Non-Small-Cell LungEGFR Gene MutationEGFR Mutation Positive Advanced Non Small Cell Lung CancerNon Small Cell Lung CancerNon-small Cell Lung Cancer

Phase 1

Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer
CompletedNCT02228369
AstraZenecaEGFR Mutation Positive Advanced Non Small Cell Lung Cancer
Start: 2014-11-05End: 2020-10-28Updated: 2021-01-05
Evaluate Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD3759
CompletedNCT03360929
LYZZ Alpha Holding LtdNon Small Cell Lung Cancer
Start: 2017-10-30End: 2020-11-13Updated: 2022-11-25

Phase 2

Phase II Umbrella Study Directed by Next Generation Sequencing
NCT03574402
Guangdong Association of Clinical TrialsCarcinoma, Non-Small-Cell Lung
Start: 2018-07-09End: 2024-12-30Target: 400Updated: 2022-12-06
First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases
CompletedNCT03653546
Alpha Biopharma (Jiangsu) Co., Ltd.Brain Metastases, EGFR Gene Mutation, Non-small Cell Lung Cancer
Start: 2018-10-29End: 2022-07-12Updated: 2025-09-10

Related Papers

First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trial.
2024-10-099 citations
Efficacy, safety and dose selection of AZD3759 in patients with untreated <i>EGFR</i>-mutated non-small-cell lung cancer and central nervous system metastases in China (CTONG1702-Arm 8): a multi-center, single-arm, phase 2 trial.
2023-09-227 citations
First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trial.
2023-07-2439 citations
Randomized phase 3 study of first-line AZD3759 (zorifertinib) versus gefitinib or erlotinib in EGFR-mutant ( <i>EGFR</i> m <sup>+</sup> ) non–small-cell lung cancer (NSCLC) with central nervous system (CNS) metastasis.
Journal of Clinical Oncology2023-06-0111 citations
Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer.
2023-02-227 citations
Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis.
2019-12-27110 citations
Osimertinib for patients (pts) with leptomeningeal metastases (LM) associated with EGFRm advanced NSCLC: The AURA LM study
Annals of Oncology2019-04-013 citations
Non-small cell lung cancer leptomeningeal metastases treated with intrathecal therapy plus osimertinib and temozolomide and whole-brain radiation therapy: a case report.
2018-08-1011 citations
Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study.
2017-10-1989 citations
Osimertinib for patients (pts) with leptomeningeal metastases (LM) from EGFR-mutant non-small cell lung cancer (NSCLC): Updated results from the BLOOM study.
Journal of Clinical Oncology2017-05-2094 citations
Complete clearance of plasma EGFR mutations as a predictor of outcome on osimertinib in the AURA trial.
Journal of Clinical Oncology2017-05-2040 citations
Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in patients with TKI-naïve, EGFRm NSCLC with CNS metastases.
Journal of Clinical Oncology2017-05-2017 citations
Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in EGFRm NSCLC patients with leptomeningeal metastasis (LM) who progressed after other anti-cancer therapy.
Journal of Clinical Oncology2017-05-2015 citations
Osimertinib activity in patients (pts) with leptomeningeal (LM) disease from non-small cell lung cancer (NSCLC): Updated results from BLOOM, a phase I study.
Journal of Clinical Oncology2016-05-2094 citations
Phase I study of AZD3759, a CNS penetrable EGFR inhibitor, for the treatment of non-small-cell lung cancer (NSCLC) with brain metastasis (BM) and leptomeningeal metastasis (LM).
Journal of Clinical Oncology2016-05-2041 citations
AZD3759, an EGFR inhibitor with blood brain barrier (BBB) penetration for the treatment of non-small cell lung cancer (NSCLC) with brain metastasis (BM): Preclinical evidence and clinical cases.
Journal of Clinical Oncology2015-05-2032 citations